AQP4 and myeloid sarcoma: Because treatments of MS and NMOSDs are different, and disease modifying treatments for MS can induce severe exacerbations serological testing for AQP4 and MOG should be done in patients with features suggestive of NMOSDs, particularly in populations at high risk (25) (Table 1).